<DOC>
	<DOCNO>NCT00749723</DOCNO>
	<brief_summary>The purpose study improve overall survival maintain good quality life pediatric patient refractory recurrent brain tumor ( medulloblastomas , supratentorial PNETs , ependymomas WHO grade II III ) . Response different chemotherapy option ( intravenous versus oral chemotherapy , intraventricular chemotherapy ) part multimodal therapy assess . Progression-free , overall survival toxicity evaluate additionally .</brief_summary>
	<brief_title>Therapy Optimization Trial Treatment Relapsed Refractory Brain Tumors Children</brief_title>
	<detailed_description>Parts study : P-HIT-REZ-2005 : trial treatment relapse PNETs ( medulloblastomas , supratentorial PNETs ) E-HIT-REZ-2005 : trial treatment relapse ependymomas ( Phase II-Study temozolomide ) Phase II-Study : intraventricular therapy etoposide neoplastic meningitis relapse PNETs ependymomas subarachnoid tumor manifestation ( window study )</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Trofosfamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>Disease Characteristics Histologically confirm Medulloblastoma , cerebral PNET Ependymoma Refractory relapse disease Measurable disease MRI detection tumor cell cerebrospinal fluid Patients characteristic Performance status ECOG ≥ 3 Karnofsky Status ≥ 40 % Life expectancy ≥ 8 week Hematological : Absolute leukocyte count ≥ 2.0 x 10^9 /l Hemoglobin ≥ 10g/dl Platelet count ≥ 70 x 10^9/l Renal : Creatinine great 1.5 time UNL No overt renal disease Hepatic : Bilirubin le 2.5 time UNL AST ALT less 5 time UNL No overt hepatic disease Pulmonary : No overt pulmonary disease Cardiovascular : No overt cardiovascular disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection Prior concurrent therapy More 2 week since prior systemic chemotherapy More 4 week since prior radiotherapy No concurrent anticancer experimental drug Examinations require Examination lumbar CSF Cranial spinal MRI within 14 day prior start treatment</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>brain tumor</keyword>
	<keyword>relapse</keyword>
	<keyword>child</keyword>
	<keyword>etoposide</keyword>
	<keyword>intraventricular</keyword>
	<keyword>temozolomide</keyword>
</DOC>